In the latest trading session, 0.42 million Outlook Therapeutics Inc (NASDAQ:OTLK) shares changed hands as the company’s beta touched 0.47. With the company’s most recent per share price at $1.23 changing hands around $0.09 or 7.46% at last look, the market valuation stands at $39.96M. OTLK’s current price is a discount, trading about -711.38% off its 52-week high of $9.98. The share price had its 52-week low at $0.87, which suggests the last value was 29.27% up since then. When we look at Outlook Therapeutics Inc’s average trading volume, we note the 10-day average is 0.36 million shares, with the 3-month average coming to 579.78K.
Analysts gave the Outlook Therapeutics Inc (OTLK) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.40. If we narrow down to specifics, the data shows that 0 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended OTLK as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight. Outlook Therapeutics Inc’s EPS for the current quarter is expected to be -0.55.
Outlook Therapeutics Inc (NASDAQ:OTLK) trade information
Instantly OTLK is in green as seen in intraday trades today. With action 0.41%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -35.19%, with the 5-day performance at 0.41% in the green. However, in the 30-day time frame, Outlook Therapeutics Inc (NASDAQ:OTLK) is -13.12% down. Looking at the short shares, we see there were 3.93 million shares sold at short interest cover period of 8.45 days.
Outlook Therapeutics Inc (OTLK) estimates and forecasts
Consensus estimates given by 5 financial analysts project the company’s revenue in the current quarter to hit an average of 702.6k. 5 analysts are of the opinion that Outlook Therapeutics Inc’s revenue for the current quarter will be 2.26M. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 36.59%. The 2025 estimates are for Outlook Therapeutics Inc earnings to increase by 56.08%.
Outlook Therapeutics Inc (NASDAQ:OTLK)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 36.42% of Outlook Therapeutics Inc shares while 16.60% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 26.11%. There are 16.60% institutions holding the Outlook Therapeutics Inc stock share, with GREAT POINT PARTNERS LLC the top institutional holder. As of 2024-06-30, the company held 7.3255% of the shares, roughly 1.7 million OTLK shares worth $12.56 million.
TANG CAPITAL MANAGEMENT LLC holds the second largest percentage of outstanding shares, with 6.9721% or 1.62 million shares worth $11.95 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF. With 442.51 shares estimated at $0.52 million under it, the former controlled 1.38% of total outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held about 1.15% of the shares, roughly 368.29 shares worth around $0.43 million.
